This is a preprint.
Genetic association of preeclampsia to von Willebrand factor and its size-regulator ADAMTS13
- PMID: 40671815
- PMCID: PMC12265156
- DOI: 10.21203/rs.3.rs-5685318/v1
Genetic association of preeclampsia to von Willebrand factor and its size-regulator ADAMTS13
Abstract
Preeclampsia is a common pregnancy-specific vascular disorder that develops during the second half of pregnancy. Preeclampsia shares features with thrombotic microangiopathies. Here we analyzed whether sequence variants in the coagulation system genes predispose to preeclampsia. We performed targeted exomic sequencing of 58 genes in a total of 615 preeclamptic women and 2094 controls. A common missense variant rs1800385 (Val1565Leu) in the gene coding for von Willebrand Factor (VWF) (OR=1.72, p-value=3.57E-4) and a low-frequency missense variant rs41314453 (Ala732Val) in the gene coding for a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) (OR=1.97, p-value=0.044) were associated with preeclampsia. rs41314453 is known to decrease ADAMTS13 expression and activity. Thus, the reduced enzyme activity could promote the formation of large vWF polymers on endothelial cells and platelets and thereby increase vascular prothrombotic activity in preeclampsia. Our results support a role for an impaired ability of ADAMTS13 to limit VWF polymerization in the pathogenesis of PE. Ultralarge multimers of VWF could mediate platelet accumulation in the turbulent intervillous spaces in preeclamptic placentae, calling upon novel therapeutics to control the VWF-ADAMTS13 axis in severe cases having low ADAMTS13 in the presence of high VWF levels and multimerization.
Keywords: ADAMTS13; coagulation cascade; genetic association; preeclampsia; pregnancy; von willebrand factor.
Conflict of interest statement
Additional Declarations: Competing interest reported. RL is a member of an advisor board and given lectures for Sanofi and Takeda. AJ serves on the scientific advisory boards of Alexion, AstraZeneca Rare Disease, and Novartis International AG, and serves as a consultant for Dianthus Therapeutics and Aurinia Pharmaceuticals. She has been a Principal Investigator for Apellis Pharmaceuticals and is a Principal Investigator for Novartis International AG. She also receives royalty from UptoDate. HL has received honoraria from Orion Corporation. JPA is in the Scientific Advisory Board of Complement Corporation and Kypha, Inc; Scientific Advisory Board. Furthermore, he serves as a consultant in Celldex Therapeutics, formerly Avant Immunotherapeutics, Inc., Biothera and Clinical Pharmacy Services, CDMI. SM has received honoraria from Alexion, AstraZeneca Rare Disease, Biogen, Merck, Pfizer and UCB, and research funding from Alexion. Other authors have no conflicts of interest to report.
Figures



References
-
- Van Lerberghe W., Manuel A., Matthews Z. & Cathy W. The World Health Report 2005 - Make Every Mother and Child Count. (2005).
-
- McCrae K. R. Thrombocytopenia in pregnancy. Hematology.American Society of Hematology.Education Program 2010, 397–402 (2010). - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous